New Data Reinforce Long-Term Benefit of Emicizumab for Patients With Hemophilia A
December 11th 2020The data presented at ASH 2020 build on results previously observed in the pivotal HAVEN clinical trial among adults, adolescents, and children with hemophilia A, with and without factor VIII inhibitors.